A Phase I, Partially Blind (Observer-blind), Randomized, Single Dose Ascending Study of Dengue Monoclonal Antibody (Dengushield) in Healthy Adults
Latest Information Update: 04 Nov 2021
At a glance
- Drugs Dengushield Serum Institute of India (Primary)
- Indications Dengue
- Focus Adverse reactions
- Sponsors Serum Institute of India
- 15 Feb 2020 Status changed from active, no longer recruiting to completed.
- 15 Oct 2019 Status changed from not yet recruiting to active, no longer recruiting.
- 19 Jun 2019 Planned number of patients changed from 40 to 52.